An optimized clinical regimen for the oncolytic virus PV701

Clinical Cancer Research

Volumn 13, Issue 3, 2007, Pages 977-985

  Hotte, Sébastien J ^a   Lorence, Robert M ^b   Hirte, Hal W ^a   Polawski, Susan R ^a   Bamat, Michael K ^b   O'Neil, James D ^b   Roberts, M Scot ^b   Groene, William S ^b   Major, Pierre P ^a  

^a JURAVINSKI CANCER CENTRE   (Canada)

^b Wellstat Therapeutics Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ONCOLYTIC VIRUS; PROBIOTIC AGENT; PV 701;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ABDOMINAL SWELLING; ADULT; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ANXIETY; ARTHRALGIA; ARTICLE; BACKACHE; CANCER; CANCER PAIN; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIAPHORESIS; DIARRHEA; DIZZINESS; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; GASTROINTESTINAL HEMORRHAGE; HEADACHE; HUMAN; HYPERTENSION; HYPOKALEMIA; HYPOTENSION; INFUSION REACTION; INJECTION SITE PAIN; INSOMNIA; LEG PAIN; LEUKOPENIA; LIPOSARCOMA; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NERVOUSNESS; NEUTROPENIA; OVARY CANCER; PARTIAL THROMBOPLASTIN TIME; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHINITIS; SIDE EFFECT; TACHYCARDIA; TASTE DISORDER; THORAX PAIN; THROMBOCYTOPENIA; VIREMIA; VOMITING;

ADULT; ANTIBODIES; CLINICAL PROTOCOLS; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TIME FACTORS; TREATMENT OUTCOME;

EID: 33847417019     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1817     Document Type: Article

References (19)

1. Kirn DH. The end of the beginning. Oncolytic virotherapy achieves clinical proof-of-concept. Mol Ther 2006;13:237-8.
2. Kirn DH, McCormick F. Replicating viruses as selective cancer therapeutics. Mol Med Today 1996;2:519-27.
3. Nemunaitis H, Edelman J. Selectively replicating viral vectors. Cancer Gene Ther 2002;9:987-1000.
4. Bell JC, Garson K, Lichty B, Stojdl D. Oncolytic viruses: programmable tumour hunters. Curr Gene Ther 2002;2:243-54.
5. Roberts MS, Lorence RM, Groene WS, Bamat MK. Naturally oncolytic viruses. Curr Opin Mol Ther 2006;8:314-21.
6. Pecora AL, Rizvi N, Cohen GI, et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol 2002;20:2251-66.
7. Laurie SA, Bell JC, Atkins HL, et al. A phase 1 clinical trial of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin Cancer Res 2006;12:2555-62.
8. Lorence RM, Pecora AL, Major MM, et al. Overview of phase I studies of intravenous administration of PV701, an oncolytic virus. Curr Opin Mol Ther 2003;5:618-24.
9. Freeman AI, Zakay-Rones Z, Gomori JM, et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. Mol Ther 2006;13:221-8.
10. Lorence RM, Roberts MS, Groene WS, et al. Replication-competent, oncolytic Newcastle disease virus for cancer therapy. In: Hernaiz Driever P, Rabkin S, editors. Replication-competent viruses for cancer therapy. Basel (Switzerland): Karger AG; 2001. pp. 160-82.
11. Welch AR, McDaniel GP, Groene WS, et al. PV701, an oncolytic virus, targets multiple levels of antiviral dysfunction in tumor cells. Cancer Gene Ther 2003;10:S15.
12. Krishnamurthy S, Takimoto T, Scroggs RA, et al. Differentially regulated interferon response determines the outcome of Newcastle disease virus infection in normal and tumor cell lines. J Virol 2006;80:5145-55.
13. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-5.
14. Bell JC, Lichty B, Stojdl D. Getting oncolytic virus therapies off the ground. Cancer Cell 2003;4:7-11.
15. Stojdl DF, Lichty BD, ten Oever BR, et al. VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell 2004;4:263-75.
16. Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer 2005;5:965-76.
17. Lorence RM, O'Neil JD, Pecora AL, et al. PV701, a replication-competent oncolytic virus: preclinical and clinical desensitization to acute toxicity allows for marked intravenous dose intensification. Proc. AACR-NCI-EORTC International Conference 2001;60.
18. Bergsland EK, Venook AP. Shedding old paradigms: developing viruses to treat cancer. J Clin Oncol 2002;20:2220-2.
19. Sze DY, Freeman SM, Slonin SM, et al. Dr. Gary J. Becker Young Investigator Award: Intraarterial adenovirus administration for metastatic gastrointestinal cancer: activity, radiographic response, and survival. J Vasc Interv Radiol 2003;14:279-90.